4,4,4-trifluoro-1-(1-cyclohexenyl)-1,3-butanedione | 343629-60-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,4,4-trifluoro-1-(1-cyclohexenyl)-1,3-butanedione
• 英文别名: 1-(cyclohexen-1-yl)-4,4,4-trifluorobutane-1,3-dione
• CAS: 343629-60-7
• 化学式: C₁₀H₁₁F₃O₂
• 分子量: 220.191
• InChiKey: FVGJTVWQNKJTEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,4,4-trifluoro-1-(1-cyclohexenyl)-1,3-butanedione 在 三乙胺 、 甲烷磺酰基叠氮化物 作用下， 以 水 、 乙腈 为溶剂， 反应 6.5h， 生成 diazo-1-acetylcyclohexenone
  参考文献：
  名称：

  DETRIFLUOROACETYLATIVE DIAZO GROUP TRANSFER: (E)-1-DIAZO-4-PHENYL-3-BUTEN-2-ONE

  摘要：

  DOI：

  10.15227/orgsyn.073.0134
• 作为产物：
  描述：

  三氟乙酸2,2,2-三氟乙酯 、 乙酰基环已烯 在 正丁基锂 、 六甲基二硅氮烷 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.09h， 生成 4,4,4-trifluoro-1-(1-cyclohexenyl)-1,3-butanedione
  参考文献：
  名称：

  DETRIFLUOROACETYLATIVE DIAZO GROUP TRANSFER: (E)-1-DIAZO-4-PHENYL-3-BUTEN-2-ONE

  摘要：

  DOI：

  10.15227/orgsyn.073.0134

文献信息

• Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
  申请人：Pfizer Inc.

  公开号：US06531492B1

  公开（公告）日：2003-03-11

  The present invention relates to compounds of the formula wherein R2, R3, R6 and A are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).

  本发明涉及公式中R2、R3、R6和A如规范中定义的化合物，以及含有它们的药物组合物和它们的药用。本发明的化合物在治疗或缓解炎症和其他与炎症有关的疾病中有用，如骨关节炎、类风湿性关节炎、结肠癌和阿尔茨海默病，在哺乳动物（最好是人类、狗、猫和家畜）中。
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  作者：Thomas D. Penning、John J. Talley、Stephen R. Bertenshaw、Jeffery S. Carter、Paul W. Collins、Stephen Docter、Matthew J. Graneto、Len F. Lee、James W. Malecha、Julie M. Miyashiro、Roland S. Rogers、D. J. Rogier、Stella S. Yu、Gary D. Anderson、Earl G. Burton、J. Nita Cogburn、Susan A. Gregory、Carol M. Koboldt、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Yan Y. Zhang、Peter C. Isakson

  DOI：10.1021/jm960803q

  日期：1997.4.1

  A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.
• HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS
  申请人：Pfizer Products Inc.

  公开号：EP1233959B1

  公开（公告）日：2005-03-16
• US6531492B1
  申请人：——

  公开号：US6531492B1

  公开（公告）日：2003-03-11
• [EN] HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS<br/>[FR] DERIVE HETEROCYCLO-ALKYLSULFONYLE PYRAZOLE EN TANT QU'AGENTS ANTI-INFLAMMATOIRES/ANALGESIQUES
  申请人：PFIZER PROD INC

  公开号：WO2001040216A1

  公开（公告）日：2001-06-07

  The present invention relates to compounds of formula (I) wherein R?2, R3, R6¿ and A are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).